A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.

Rui Hua Xu,Li Y,Jiao Ji,Miaozhen Qiu,Yang Zhang,Wenqin Liu,Xiaohong Tian,Su Li,Hengbang Wang,Fenghua Wang,Dongsheng Zhang,Feng Wang,Zhi Qiang Wang,Huiyan Luo,Benyan Zou,De-shen Wang,Chao Ren,Ying Jin,Yifan Zhai,Dajun Yang

A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.

2018

2593Background: APG-1387 is a bivalent small molecule Smac mimetic that antagonizes the IAPs. Preclinical studies have shown its dose- and schedule-dependent, strong antitumor activities in multipl...

Keywords:

Cancer research
Pathology
Medicine
in patient
Bivalent (genetics)
phase i study
Small molecule
smac mimetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations